Treatment Pipeline
There are now more than 190 trials underway testing nearly 160 experimental treatments for Alzheimer’s Disease across the globe, with almost 40 of them in Phase 3 trials. The treatment pipeline is growing, and for the first time, we have approved drugs, lecanemab and donanemab, that can slow cognitive decline in early-stage Alzheimer’s. These treatments are available in several countries, including the UK. Yet neither is offered on the NHS. Treatments are also being developed to manage symptoms and enhance cognitive function.
Estimated number of drug candidates for a single success in Alzheimer’s disease drug development compared to the average
drug
pipeline
clinical
trial
recruitment
Calcoen et al. (2015) What does it take to produce a breakthrough drug? Nat Rev Drug Discovery.